🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,413 results for “Chinese” Clear

  1. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  2. Rifaximin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial

  3. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Severe Aplastic Anemia

    phase 2 small molecule active

    1 trial

  4. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  5. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  6. Rituximab Paclitaxel Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  8. Romiplostim

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule completed

    1 trial

  9. Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    aGVHD

    phase 2 small molecule completed

    1 trial

  10. Ruxolitinib 5 MG BID Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

    phase 2 small molecule active

    1 trial

  11. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  13. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  14. SHR-A1921 injection and adebrelimab injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  15. SIRT Yttrium-90

    Chinese University of Hong Kong

    Cholangio Carcinoma

    phase 2 small molecule completed

    1 trial

  16. SOX Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  17. SR419

    Shanghai University of Traditional Chinese Medicine

    Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  18. SS-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  19. Sacituzumab Tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. Sacituzumab Tirumotecan and Limertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR-mutant Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Sacituzumab tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC - Triple-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial

  23. Sindillimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  24. Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources